Business and Organization - Subsequent Events (Details) - Castle Creek Pharmaceuticals, LLC Co-Development And License Agreement - Subsequent Event	Apr. 12, 2019 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment received	$ 7,500,000
First milestone payment receivable	2,500,000
Castle Creek Pharmaceuticals, LLC
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum development costs payable by other party	$ 20,000,000
Excess costs payable by other party (percent)	70.00%
Excess costs payable (percent)	30.00%
Upfront payment received	$ 7,500,000
First milestone payment receivable	2,500,000
Second milestone payment receivable	30,000,000
Maximum sales milestone payments receivable	75,000,000
First sales milestone payment receivable	25,000,000
First product sales threshold for sales milestone payments	250,000,000
Second sales milestone receivable	50,000,000
Second product sales threshold for sales milestone payments	$ 750,000,000
Gross profit receivable from other party (percent of product sales)	30.00%
Term of arrangement (years)	40 years
Days written notice required to terminate (days)	180 days
Intrexon Corporation | Exclusive Channel Collaboration Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments due to third party	50.00%